You are currently viewing MOWOOT voted ‘Best Medical Device Company’ at international Investor Conference RESI EUROPE 2020

MOWOOT voted ‘Best Medical Device Company’ at international Investor Conference RESI EUROPE 2020

Among 23 companies, in a very special all digital RESI conference edition, MOWOOT was voted as the best medical device company of the event, and even made 2nd place in the overall rating of most voted companies.
The Redefining Early Stage Investments (RESI) Conference is an ongoing conference series that has established a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding.
The RESI Conference series is organized by Life Science Nation (LSN) (Boston, MA, USA), and brings together a global gathering of early-stage life science entrepreneurs (in the fields of therapeutics, medical device, diagnostics, digital health, etc.) and investors, helping them build valuable connections for investment or partnership.
“RESI was founded to provide scientist-entrepreneurs with a venue to connect with a diverse range of active investors who are a fit for their opportunities.” Dennis Ford CEO of LSN & creator of RESI conference.
RESI EUROPE 2020 (for the first time ever 100% digital)
On March 23rd-25th 2020 the RESI EUROPE 2020 conference, originally scheduled to be held in Paris (France), was held in a complete digital format for the first time ever, leading to a record in attendance, as investors from all around the world were able to partake directly from their (home) office.
In 3 days, more than 1200 video partnering meetings took place, 70% of which were investor company meetings. Additionally a Virtual Exhibition Hall provided access to excellent Investor panels and Workshops that were pre-recorded in the days leading up to the conference, as well as virtual Pitch Sessions and an Innovation Challenge with exhibitions and online voting.
RESI is world renowned for its Innovation Challenge where, at every RESI conference, select companies that have been scored and ranked with the LSN expert system for “investability” are featured in the categories Medical Devices, Digital Health, Therapeutics and Diagnostics.
The 23 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge Final and present their technologies in an exhibition-style format throughout the 3 day RESI EUROPE 2020 conference.
These Innovation Challenge exhibitions were also held in digital format for the first time, with each finalist company having a dedicated page where you could view their poster, short pitch, and other supplementary materials that the companies made available for viewing.
After carefully reviewing the company exhibitions from the investor’s point of view, RESI attendants had the possibility to vote for the most innovative and promising companies in the RESI INNOVATION CHALLENGE.
MOWOOT was voted as the best company in the medical device category of the event, and even made 2nd place in the overall rating of most voted companies.
“We are pleased to see that not only patients and medical doctors see the value of MOWOOT, but also investors. This recognition is positively affecting our fundraising by adding an international angle, and will allow us to reach more markets and patients in shorter time.” Dr. Markus Wilhelms, CEO & co-founder of MOWOOT
MOWOOT is currently raising a Series A investment round to drive international expansion of the company in the European public healthcare reimbursement markets. The round has a goal of € 1,6 million and is dedicated to business angels, family offices and small VC funds alike.
MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a novel, purely physical, non-drug, non-invasive solution.
The medical device “MOWOOT Intestinal-transit management system”, which is on the market since 2018, administers the proprietary Intermittent-Colonic-Exo-peristalsis treatment to solve a huge unmet need for patients with intestinal transit disorders like Neurogenic Bowel Disorder (NBD), Opioid-Induced Constipation (OIC) and Chronic Idiopathic Constipation (CIC). The global market for these 3 clinical indications is estimated to be more than $ 15 billion annually with a healthy CAGR of over 7%, driven by an over-aging society and the need for homecare of chronic patients. Future products will also be addressing the OTC Health market.
MOWOOT, constituted in 2014, is based in Barcelona (Spain) and emerged out of the MOEBIO design Health Barcelona program (part of EIT Health Innovation Fellowships) for need-driven innovation in healthcare, in collaboration with leading European Neuro-rehabilitation hospital Institute Guttmann.